Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07305259 · ClinicalTrials.gov registry record · Early Phase 1
Researching Economical Adjuvants to Cancer Therapy
A Early Phase 1 study of Healthy Participants, sponsored by Florida State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07305259: Recruiting Early Phase 1 study of Healthy Participants, sponsored by Florida State University.
NCT07305259 is a Early Phase 1 study of Healthy Participants that is actively recruiting participants, run by Florida State University. The registered enrollment target is 60 participants, roughly in line with the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07305259, a Early Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Florida State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if beta-glucan (a dietary fiber) improves the function of the immune system in adults. It will also tell the investigators if combining beta-glucan with single bouts of exercise provides additional benefit. The main questions it aims to answer are: 1. Does beta-glucan change the ability of immune cells to recognize cancer cells? 2. Does exercise change the type of immune cells in the blood? Researchers will compare beta-glucan to a placebo (a look-alike substance with no effect) to see if beta-glucan could improve immune function against cancer. Participants will: 1. Take beta-glucan or a placebo daily for 4 weeks. 2. Visit the laboratory for three exercise tests. 3. Provide blood samples so researchers can study immune system cells.
Primary Outcome
The ability of participant peripheral blood mononuclear cells (PBMCs) to kill target cancers cells in vitro. PBMCs will be co-cultured with cancer cells for four hours, and the number of cancer cells killed over time will be quantified with flow cytometry (e.g., CD71+ labeled cancer cells with compromised cell membranes).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Beta-glucan
Study Locations (1)
Florida
- Institute of Sports Sciences and Medicine - Tallahassee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2029-09-30 |
| Phase | Early Phase 1 |
What NCT07305259 shows while recruiting
NCT07305259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07305259 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07305259 about?
NCT07305259 is a clinical study titled "Researching Economical Adjuvants to Cancer Therapy". The goal of this clinical trial is to learn if beta-glucan (a dietary fiber) improves the function of the immune system in adults. It will also tell the investigators if combining beta-glucan with single bouts of exercise provides additional benefit. The main questions it aims to answer are: 1. Doe...
What is the current status of trial NCT07305259?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2025-11-12. Estimated completion is 2029-09-30.
What conditions does trial NCT07305259 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07305259?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Beta-glucan (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07305259?
This trial is sponsored by Florida State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07305259 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07305259's enrollment target sits among peer trials
60 39th of 119 higher than 78 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
RECRUITING · Early Phase 1
-
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
RECRUITING · Early Phase 1
-
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
COMPLETED · Early Phase 1
-
Washington University WU 409: Immune Responses to Rabies Vaccine.
COMPLETED · Early Phase 1
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI